Jumonji domain containing 5 is a potential prognostic indicator in non-small cell lung cancer patients who received platinum-based chemotherapy
Open Access
- 1 November 2019
- journal article
- research article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 8 (7) , 2535-2542
Abstract
Background: Platinum-based chemotherapy is the cornerstone of non-small cell lung cancer (NSCLC) therapy. However, the molecular mechanisms and predictive markers of platinum chemoresistance have not been fully understood. Our recent study revealed that Jumonji domain containing 5 (JMJD5) expression in cells was elevated under DNA damage by alkylating agent or UV radiation, which suggests a potential role of JMJD5 in DNA damage related chemoresistance. However, the role of JMJD5 in NSCLC chemotherapy has not been reported. In this study, we demonstrated JMJD5 as a potential prognostic indicator in NSCLC patients who received platinum-based chemotherapy. Methods: JMJD5 protein expression level in tumor and adjacent normal tissues were detected by immunohistochemistry. Samples were from primary NSCLC patients who received platinum-based chemotherapy after surgical resection. Survival curves were presented by the Kaplan-Meier method and p value was acquired by log-rank test. Multivariate analysis was tested by Cox proportional-hazards regression method. Results: Elevated JMJD5 expression was found in 27.2% cases of tumor tissues (22/81), and high JMJD5 expression were significantly associated with poor overall survival time (OS) [HR =2.881 (1.774–9.121), P=0.001] and progression-free survival time (PFS) [HR =2.255 (1.417–5.886), P=0.004] in NSCLC patients who received platinum-based chemotherapy. In multivariate analyses, JMJD5 was proved to be an independent prognostic indictor for shorter OS [HR =2.339 (1.158–4.724), P=0.018] and PFS [HR =2.031 (1.095–3.767), P=0.025). Conclusions: High JMJD5 expression indicated a worse prognosis in NSCLC patients who received platinum-based chemotherapy, and JMJD5 may serve as a novel predictive marker in NSCLC chemotherapy.Keywords
This publication has 22 references indexed in Scilit:
- JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2015
- Jmjd5 functions as a regulator of p53 signaling during mouse embryogenesisCell and tissue research, 2015
- JMJD5 Regulates Cell Cycle and Pluripotency in Human Embryonic Stem CellsStem Cells, 2014
- JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α–mediated glucose metabolismProceedings of the National Academy of Sciences, 2013
- Structure of the JmjC-domain-containing protein JMJD5Acta Crystallographica Section D Structural Biology, 2013
- Histone demethylase JMJD5 is essential for embryonic developmentBiochemical and Biophysical Research Communications, 2012
- Jmjd5, an H3K36me2 histone demethylase, modulates embryonic cell proliferation through the regulation of Cdkn1a expressionDevelopment, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Jumonji domain protein JMJD5 functions in both the plant and human circadian systemsProceedings of the National Academy of Sciences, 2010
- KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferationProceedings of the National Academy of Sciences, 2010